Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 2 versus SER A GEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 2 versus SER A GEN.
METATENSIN #2 vs SER-A-GEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
500 mg orally once daily.
None Documented
None Documented
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination